成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

優(yōu)惠券使用說明>

暫無可領(lǐng)優(yōu)惠券

武漢佰樂博生物技術(shù)有限公司

主營產(chǎn)品:高活性重組蛋白,功能性抗體試劑,試劑盒等

客服熱線:027-65279366 18108604862

  • 電話:027-65279366 18108604862
  • 郵箱:info@biolabreagent.com
  • 網(wǎng)址:https://www.biolabreagent.com
  • 國籍:中國
  • 地址:東湖新技術(shù)開發(fā)區(qū)神墩四路666號C棟2層
  • 點擊這里給我發(fā)消息
  • 企業(yè)認(rèn)證:
  • 企業(yè)體檢:
  • CB指數(shù):58
ecombinant Romiplostim Protein, N-Fc 蛋白 ,羅米司亭Nplate (Romiplostim)
發(fā)布日期:2024/12/19 16:43:56發(fā)布人:武漢佰樂博生物技術(shù)有限公司

標(biāo)題:Recombinant Romiplostim Protein, N-Fc 重組蛋白(EHE26002),羅米司亭Nplate (Romiplostim)

 

名稱:Recombinant Romiplostim Protein, N-Fc 重組蛋白(EHE26002)

介紹:羅米司亭Nplate (Romiplostim)是一種血小板生成素(TPO)受體激動劑,模仿人體的天然TPO,旨在提升免疫性血小板減少癥(ITP)患者血小板計數(shù)。免疫性血小板減少癥(ITP)是—種罕見的、嚴(yán)重的自身免疫性疾病,特征為血液中血小板計數(shù)低(血小板減少癥)和血小板生成受損。

鏈接:https://www.antibodysystem.com/product/10466.html

產(chǎn)品購買聯(lián)系方式:027-65279366 /18108604356

郵箱 products@biolabreagent.com

QQ:2663991332

貨號:EHE26002

靶點:Romiplostim

形式:Lyophilized

純度:>90% as determined by SDS-PAGE.

表達(dá)系統(tǒng):Mammalian

蛋白質(zhì)長度:IEGPTLRQWLAARA

應(yīng)用:SDS-PAGE,WB,ELISA,Immunogen,Bioactivity testing in progress

別名:羅米司亭、Nplate、Romiplostim

儲存:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn):

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. PMID: 31545663

A Review of Romiplostim Mechanism of Action and Clinical Applicability. PMID: 34079225

Romiplostim. PMID: 18974747

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. PMID: 32499239

Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. PMID: 33249935

Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. PMID: 33152120

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. PMID: 35179784

Romiplostim: a review of its use in immune thrombocytopenia. PMID: 22316355

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia. PMID: 34308495

Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. PMID: 31239245

Romiplostim: a novel thrombopoiesis-stimulating agent. PMID: 19386944

Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review. PMID: 36550870

Romiplostim use in pregnant women with immune thrombocytopenia. PMID: 36156812

Romiplostim in chronic immune thrombocytopenic purpura. PMID: 19843480

Romiplostim management of immune thrombocytopenic purpura. PMID: 19401474

Romiplostim drug presence in pregnancy and lactation. PMID: 36848631

Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective. PMID: 27056734

Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. PMID: 22980701

Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. PMID: 19200304

Thrombopoietin receptor agonists: ten years later. PMID: 31073079

Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP). PMID: 34313512

Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description. PMID: 31116059

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. PMID: 19804691

Development of romiplostim: a novel engineered peptibody. PMID: 25578414

Romiplostim for SARS-CoV-2 Vaccine Induced Immune Thrombocytopenia. PMID: 34757966

Romiplostim: a second-generation thrombopoietin agonist. PMID: 19436840

Romiplostim for the management of perioperative thrombocytopenia. PMID: 29767837

Immune Thrombocytopenia in a Kidney Transplant Recipient Treated with Romiplostim. PMID: 35033295

Romiplostim-induced myelofibrosis. PMID: 24175353

Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. PMID: 33781612

Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. PMID: 30880797

Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies. PMID: 36050822

Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial. PMID: 37589942

The development of romiplostim for patients with immune thrombocytopenia. PMID: 21434943

A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli. PMID: 38282441

Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study. PMID: 37735543

Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. PMID: 31586022

Romiplostim in aplastic anaemia - another tool in the armamentarium. PMID: 33152102

Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. PMID: 29330464

Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. PMID: 34160821

Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim? PMID: 31214173

Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy. PMID: 28408804

Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database. PMID: 36803342

Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany. PMID: 34959233

An update on romiplostim for treatment of acute radiation syndrome. PMID: 35274632

Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report. PMID: 31232923

Romiplostim (Nplate()) as an effective radiation countermeasure to improve survival and platelet recovery in mice. PMID: 31021662

Comparability of biosimilar romiplostim with originator: Protein characterization, animal pharmacodynamics and pharmacokinetics. PMID: 36871442

Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. PMID: 20298251

Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature. PMID: 32611269

Romiplostim as Adjunctive Treatment of Refractory Amegakaryocytic Immune Thrombocytopenia in a Dog. PMID: 33115689

Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series. PMID: 30030975

Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar. PMID: 37961987

Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry. PMID: 34638135

Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. PMID: 32902132

Romiplostim in the management of the thrombocytopenic surgical patient. PMID: 26033367

Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. PMID: 29683946

Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome. PMID: 33131064

Romiplostim for management of chemotherapy-induced thrombocytopenia. PMID: 24414994

Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. PMID: 28150377

A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia. PMID: 33003146

Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India. PMID: 35467751

Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study. PMID: 32876852

Romiplostim dose-response in patients with myelodysplastic syndromes. PMID: 23171070

The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. PMID: 22533524

Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy-induced thrombocytopenia. PMID: 25754671

Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. PMID: 27103127

Romiplostim as early treatment for refractory primary immune thrombocytopenia. PMID: 24068656

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial. PMID: 31805185

Quality by Design in Downstream Process Development of Romiplostim. PMID: 36439274

Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. PMID: 32311075

High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. PMID: 32616921

[Pharmacological and clinical profile of romiplostim (Romiplate() 250 g for s.c. injection)]. PMID: 21747207

Romiplostim as a Therapeutic Intervention for Tacrolimus-induced Immune Thrombocytopenia in a Pediatric Cardiac Transplant Patient. PMID: 33181586

Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity. PMID: 26066765

Fate Determination Role of Erythropoietin and Romiplostim in the Lineage Commitment of Hematopoietic Progenitors. PMID: 35489782

Severe romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITP. PMID: 25325908


相關(guān)新聞資訊
  • 2025/01/23
    免疫代謝(Immunometabolism)是近年來備受關(guān)注的新領(lǐng)域,它描述了免疫功能和代謝調(diào)節(jié)之間相互關(guān)系,促炎細(xì)胞因子的交叉調(diào)節(jié)對抗菌免疫非常關(guān)鍵。細(xì)菌感染會重編細(xì)胞新陳代謝和表觀遺傳學(xué)狀態(tài),但兩者之間的相互作用究竟如何助力宿主的抗菌防御機(jī)制,一直是免疫學(xué)領(lǐng)域亟待解開的謎團(tuán)。 2025 年 1 月 14 日,曹雪濤院士等人在Cell子刊Cell Metabolism在線發(fā)表了題為
  • 2025/01/15
    美國首例禽流感病毒(Avian influenza virus,AIV)死亡病例 據(jù)新華網(wǎng)報道,2025年1月6日,美國路易斯安那州衛(wèi)生部門報告美國首例人感染高致病性禽流感病毒H5N1死亡病例。且近期日韓均突發(fā)高致病性AIV疫情,已撲殺幾百萬只雞,AIV危機(jī)警報已至最高的嚴(yán)重級別!全球性AIV疫情來勢洶洶! 圖1. 對涉疫雞場進(jìn)行撲殺 (來源:俄羅斯衛(wèi)星通訊社)
  • 2025/01/09
    中國疾控中心日前發(fā)布了2024年第52周全國急性呼吸道傳染病哨點監(jiān)測數(shù)據(jù),流感進(jìn)入季節(jié)性流行,門診及住院病例中人偏肺病毒(HMPV)陽性檢出率呈波動上升趨勢,其中北方省份上升趨勢更明顯。 圖1:第52周呼吸道樣本病原體核酸檢測陽性率(%) (來源:中國疾病預(yù)防控制中心) HMPV簡介 人偏肺病毒(human metapneumovirus, HMPV)

查看更多

商家暫時不對外公布

主頁 | 企業(yè)會員服務(wù) | 廣告業(yè)務(wù) | 聯(lián)系我們 | 舊版入口 | 中文MSDS | CAS Index | 常用化學(xué)品CAS列表 | 化工產(chǎn)品目錄 | 新產(chǎn)品列表 | 評選活動| HS海關(guān)編碼
Copyright © 2008 ChemicalBook 京ICP備07040585號  京公網(wǎng)安備 11010802032676號  All rights reserved.
熱線電話:400-158-6606